Johnson & Johnson Valuation
Is JNJ undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of JNJ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: JNJ (€150.46) is trading below our estimate of fair value (€278.87)
Significantly Below Fair Value: JNJ is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for JNJ?
Key metric: As JNJ is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is JNJ's PE Ratio? | |
|---|---|
| PE Ratio | 25.3x |
| Earnings | US$14.77b |
| Market Cap | US$373.59b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.4x |
| Enterprise Value/EBITDA | 12.9x |
| PEG Ratio | 2.4x |
Price to Earnings Ratio vs Peers
How does JNJ's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 20.5x | ||
MRK Merck KGaA | 22.9x | 10.9% | €61.6b |
DMP Dermapharm Holding | 22.3x | 18.1% | €2.0b |
ROG Roche Holding | 19.1x | 11.1% | CHF 204.3b |
NOVN Novartis | 17.8x | 7.0% | CHF 187.3b |
JNJ Johnson & Johnson | 25.3x | 10.6% | €373.6b |
Price-To-Earnings vs Peers: JNJ is expensive based on its Price-To-Earnings Ratio (25.3x) compared to the peer average (20.5x).
Price to Earnings Ratio vs Industry
How does JNJ's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: JNJ is expensive based on its Price-To-Earnings Ratio (25.3x) compared to the European Pharmaceuticals industry average (20.3x).
Price to Earnings Ratio vs Fair Ratio
What is JNJ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 25.3x |
| Fair PE Ratio | 27.1x |
Price-To-Earnings vs Fair Ratio: JNJ is good value based on its Price-To-Earnings Ratio (25.3x) compared to the estimated Fair Price-To-Earnings Ratio (27.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €150.46 | €165.06 +9.7% | 7.3% | €202.92 | €146.29 | n/a | 23 |
| Nov ’25 | €147.40 | €161.15 +9.3% | 7.3% | €198.81 | €143.33 | n/a | 22 |
| Oct ’25 | €146.02 | €154.65 +5.9% | 8.0% | €194.08 | €135.41 | n/a | 22 |
| Sep ’25 | €148.70 | €154.77 +4.1% | 8.0% | €194.53 | €135.72 | n/a | 22 |
| Aug ’25 | €147.50 | €157.29 +6.6% | 8.0% | €198.14 | €138.24 | n/a | 22 |
| Jul ’25 | €136.00 | €157.91 +16.1% | 7.7% | €197.71 | €142.54 | n/a | 22 |
| Jun ’25 | €135.50 | €158.77 +17.2% | 7.8% | €198.53 | €143.13 | n/a | 22 |
| May ’25 | €136.36 | €161.61 +18.5% | 7.8% | €201.09 | €144.97 | n/a | 21 |
| Apr ’25 | €146.60 | €161.95 +10.5% | 7.1% | €198.51 | €147.73 | n/a | 21 |
| Mar ’25 | €149.80 | €161.03 +7.5% | 7.5% | €198.70 | €145.10 | n/a | 21 |
| Feb ’25 | €145.30 | €160.58 +10.5% | 7.4% | €197.80 | €144.44 | n/a | 22 |
| Jan ’25 | €141.70 | €160.13 +13.0% | 7.2% | €196.94 | €143.81 | n/a | 22 |
| Dec ’24 | €144.90 | €160.49 +10.8% | 7.4% | €197.69 | €142.52 | n/a | 22 |
| Nov ’24 | €141.10 | €166.29 +17.9% | 6.9% | €202.98 | €148.22 | €147.40 | 22 |
| Oct ’24 | €147.10 | €168.28 +14.4% | 6.5% | €201.22 | €147.87 | €146.02 | 21 |
| Sep ’24 | €149.00 | €168.02 +12.8% | 6.0% | €199.58 | €152.24 | €148.70 | 21 |
| Aug ’24 | €153.90 | €165.83 +7.8% | 6.1% | €195.52 | €149.14 | €147.50 | 20 |
| Jul ’24 | €151.70 | €167.68 +10.5% | 6.9% | €201.18 | €150.65 | €136.00 | 20 |
| Jun ’24 | €143.60 | €167.68 +16.8% | 6.9% | €201.18 | €150.65 | €135.50 | 20 |
| May ’24 | €148.30 | €162.98 +9.9% | 7.1% | €195.99 | €146.77 | €136.36 | 19 |
| Apr ’24 | €141.58 | €164.12 +15.9% | 7.2% | €198.34 | €148.52 | €146.60 | 21 |
| Mar ’24 | €143.10 | €168.11 +17.5% | 7.0% | €201.65 | €151.00 | €149.80 | 21 |
| Feb ’24 | €150.32 | €166.77 +10.9% | 6.5% | €198.21 | €151.19 | €145.30 | 20 |
| Jan ’24 | €166.14 | €171.16 +3.0% | 7.1% | €202.25 | €150.51 | €141.70 | 22 |
| Dec ’23 | €170.16 | €173.14 +1.7% | 7.1% | €204.25 | €152.00 | €144.90 | 20 |
| Nov ’23 | €175.14 | €186.24 +6.3% | 7.0% | €220.07 | €163.78 | €141.10 | 21 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Fortrea Holdings
US$1.8b
A contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.
K67
US$18.40
7D
2.8%
1Y
-38.7%
Amneal Pharmaceuticals
US$2.6b
Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
2DT
US$7.70
7D
1.3%
1Y
89.7%
Collegium Pharmaceutical
US$966.2m
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
354
US$29.00
7D
3.6%
1Y
22.9%